安俊涛
复方丹参滴丸联合曲美他嗪治疗冠心病伴心绞痛的临床疗效
安俊涛
【摘要】目的 探讨采用复方丹参滴丸联合曲美他嗪对冠心病伴心绞痛进行治疗的临床效果。方法 在本院2014年12月~2016年2月收治的冠心病伴心绞痛患者中抽取66例并随机分为观察组和对照组,其中对照组仅采用曲美他嗪进行治疗,观察组则采用复方丹参滴丸联合曲美他嗪进行治疗,对两组患者的临床疗效进行对比分析。结果 观察组患者的总治疗有效率高于对照组,差异具有统计学意义(P<0.05)。结论 采用复方丹参滴丸联合曲美他嗪对冠心病伴心绞痛进行治疗,可有效促进患者临床症状的改善,对于减轻其痛苦,促进患者生存质量的提高具有十分积极的作用。
【关键词】冠心病;心绞痛;曲美他嗪;复方丹参滴丸
Objective To evaluate the clinical effect of CSDP joint trimetazidine in treatment of coronary artery disease and angina. Methods In the hospital in December 2014 to February 2016 from your patients admitted to coronary artery disease and angina extract 66 cases were randomly divided into observation group and the control group,the control group using only trimetazidine treatment,the observation group use CSDP joint trimetazidine treatment,the clinical efficacy of the two groups of patients were analyzed. Results The total effective observation group were significantly higher efficiency,the difference was significant(P<0.05). Conclusion Use CSDP joint trimetazidine to coronary artery disease and angina treatment can effectively contribute to the improvement of clinical symptoms in patients,for alleviating their suffering,promote the improvement of the quality of life for patients with a very active role.
【Key words】 Coronary artery disease,Angina,Trimetazidine,CSDP
近年来我国冠心病发病率呈逐年上升趋势,由此引发的心肌缺血所致心绞痛人数也逐渐上升,对患者的生命安全造成严重影响[1]。本次研究通过对本院66例冠心病合并心绞痛采用曲美他嗪和复方丹参滴丸进行治疗的临床资料进行回顾性分析,旨在为冠心病伴心绞痛的治疗提供可靠建议。
1.1 一般资料
在本院2014年12月~2016年2月收治的冠心病伴心绞痛患者中抽取66例,以《缺血性心脏病的命名及诊断》作为入选标准,并采用随机数字表法将其分为观察组和对照组,其中对照组33例,包括18例男性,15例女性,年龄37~77岁,平均为(61.3±7.2)岁,病程平均为(3.9±1.3)年;观察组33例,包括19例男性,14例女性,年龄39~75岁,平均为(62.1±6.8)岁,病程平均为(3.8±1.4)年。……